Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Heart Association 2022-08, Vol.11 (16), p.e025045-e025045
Hauptverfasser: Li, Jing‐Wei, Arnott, Clare, Heerspink, Hiddo J. L., MBiostat, Qiang Li, Cannon, Christopher P., Wheeler, David C., Charytan, David M., Barraclough, Jennifer, Figtree, Gemma A., Agarwal, Rajiv, Bakris, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Zhang, Hong, Zinman, Bernard, Mahaffey, Kenneth W., Perkovic, Vlado, Neal, Bruce, Jardine, Meg J.
Format: Artikel
Sprache:eng
Schlagworte:
canagliflozin
chronic kidney disease
diabetes
recurrent cardiovascular event
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of canagliflozin on total (first and recurrent) cardiovascular events. Methods and Results The CREDENCE trial compared canagliflozin or matching placebo in 4401 patients with type 2 diabetes, albuminuria, and estimated glomerular filtration rate of 30 to
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.121.025045